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Introduction 
Strong evidence exists for a relationship between polypharmacy and mortality[1], 
independent of comorbidity.  The mechanisms underlying this relationship are unclear.  
Medication-related harm (MRH) may occur due to non-adherence or adverse drug 
reactions. We sought to determine if MRH due to non-adherence or adverse drug reactions 
may explain the association between polypharmacy and mortality. 
Methods 
The PRIME study recruited 1280 older adults at hospital discharge from 5 hospitals in 
England between 2013 to 2015[2]. Patients were followed up in the community for 8-weeks 
by senior pharmacists to identify MRH using data from hospital readmissions, GP records 
and patient interviews.  Mortality data at 12 months post-discharge were obtained from 
hospital records.  Non-adherence was determined using a modified version of a validated 
questionnaire[3].  Adverse drug reactions were assessed using the Naranjo algorithm[4].  
Adjusted logistic regression models were used to investigate the relationship between (1) 
number of medicines and MRH, (2) MRH and mortality.  
Results 
1116 out of 1280 patients completed follow-up (median age 82 years, range 65-103 years, 
58% female).  Patients were discharged with a median of 9 medicines (range 0-27). A higher 
number of medicines was strongly associated with MRH due to non-adherence (p<0.01) and 
adverse drug reactions (p<0.001).  In multivariable analysis, MRH due to non-adherence was 
associated with one-year all-cause mortality (OR 1.80, 95% CI 1.08-2.99, p=0.02), however 
MRH due to ADR was not (OR 1.20, 95% CI 0.86-1.68, p=0.28).  
Key Conclusions 
Harm from non-adherence to medications may explain the relationship between 
polypharmacy and mortality. 
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